Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence

Fig. 2

Mean change from baseline in triglyceride (a) and non-HDL-C (b). Non-HDL-C: Non-high-density lipoprotein cholesterol. Studies included [13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30]: Group 1 (12 weeks): Shetty et al. [13], Thacker et al. [14], Joshi et al. [15], Bhattacharyya et al. [16]; Group 2 (24 weeks): Saboo et al. [17], Joshi et al. [18], Chhaya et al. [19], Mohit et al. [20], Kaul et al. [21], Goyal et al. [22]; Group 3 (27 weeks): Chatterjee et al. [23]; Group 4 (36 weeks): Joshi et al. [24]; Group 5 (40 weeks): Chatterjee et al. [25]; Group 6 (52 weeks): Joshi et al. [26], Aneja et al. [27], Maheshwari et al. [28], Chatterjee et al. [29]; Group 7 (58 weeks): Chatterjee et al. [30]. Mean non-HDL-C calculation: data not available for Thacker et al. [14], Saboo et al. [17], Joshi et al. [18], Chhaya et al. [19], Mohit et al. [20], Goyal et al. [22]

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840